Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benaglutide with Metformin and Lifestyle for PCOS and Obesity
NCT06775093Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Randomised, open-label trial of beinaglutide in polycystic ovary syndrome (PCOS) and obesity (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Live birth rate at 18 months. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
beinaglutide
03
Conditions
polycystic ovary syndrome (PCOS)obesity
Beyond the preview
Go deeper on NCT06775093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06775093.